Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
about
Breast cancer brain metastases: the last frontierHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsOverview of the CLEOPATRA Trial: Implications for Advanced PractitionersTargeted Therapies for Brain Metastases from Breast CancerBreast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.The expanding role of pertuzumab in the treatment of HER2-positive breast cancerQuantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain MetastasesMeaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Breast cancer in 2014: A call back to reality!Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?Histopathologic diagnosis of brain metastases: current trends in management and future considerations.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Management of patients treated with pertuzumab in the Australian clinical practice setting.Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis.Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases.Challenges of developing small molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels.Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer.Mechanisms and Therapy for Cancer Metastasis to the Brain.Medicine: Eyes on the target.Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies.Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
P2860
Q26775663-65751BBE-86F6-42EA-B672-B2CA9B1055CBQ26777681-56A61E1B-5200-4AF1-9A50-58F596A10C9BQ28066819-996B99C1-97F5-42C9-A066-DA024CABBE2FQ28068154-259DA200-0B00-45CC-964F-B4383E8CAB91Q30238959-15CBE506-D4B0-448C-A56D-E36EA68F70EFQ30239901-E393782F-3216-4E80-93DB-3C77B1359DD9Q31154571-7EDCF434-62A1-464A-A57A-85AA1116D670Q35551911-371FE2C4-6D73-4E57-9868-73D618B19C25Q35653163-93EB4448-DD35-4249-ABD4-D2841944FA7BQ36107363-CE0B497B-5A8E-497F-9295-F31F752689C2Q36843741-D4BE7D50-CDD5-43F7-A8F7-5A46553F8879Q37398492-6E53B9D7-83BE-47F4-96F6-1AAC1A8AB44BQ38269966-3A768D85-435A-4537-A724-009A749AA68AQ38286163-0C201F73-FB28-45B8-95CF-968DAACBAB8FQ38308031-3DDF8547-CA0E-4FAE-A305-3E94DF2AC87EQ38385463-26AD1C9D-4929-4FFC-9B18-42EB7DD04449Q38573858-3FE95522-302C-48C9-8890-289D064F4285Q38575259-8983A063-3989-44C0-A106-738CB517CE94Q38616628-D52AB385-F73D-4E24-A282-202B12C24460Q38791747-37AD9D35-D7F8-4DBC-9CA0-0273E926C092Q38829087-AD471342-C490-4D25-ADE9-707970477445Q38850594-8E57D049-718F-4633-B6D9-FCB0BC5D5274Q38903136-20BB6BD2-54D0-463B-B210-A1A3F8462EEAQ40932062-DB63EA61-E338-497C-B2B7-1B9D334D8E55Q42367836-2357BDDC-9593-4BBD-B348-B28A5A7ECDA6Q47103332-B5F51AE4-DEC2-479E-AD10-6FFB13350E71Q47152190-E10CDFEA-430B-4150-9E46-178B52024936Q47279118-311A29B1-C1CE-4891-A596-4C4D9F1E2EFAQ47824250-08A41CC4-C0F3-48E0-B0AC-627270EB6B84Q47827169-4134EE5F-1FB0-4751-8FA0-115798D49F67Q47839509-DD428A12-4703-4787-815F-8C0443694CB8Q48106837-5560F9D6-CD7C-4838-AF37-E43ECAFE1822Q48115621-FC0CFD57-D8D5-40BF-93DD-9465AC20AB99Q48162978-AC8B51B1-E3BB-490B-B465-3B24ED083CBDQ52578959-93B97A93-E5B6-414A-BC6C-9E237A661568Q54940766-0ADA386A-BEDF-4E1E-95EF-B810B3258DECQ54950354-768347E0-6851-4181-82A7-0A7EE603724EQ55036430-8F81266C-BAD1-42A2-ADBF-1ACBF35440F8Q55287222-55941FDF-45B6-4577-88DF-21E4701D2991Q55394663-E2BC06C1-C3CD-4C31-9DEE-E53B541B3C3F
P2860
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Incidence of central nervous s ...... zed phase III study CLEOPATRA.
@ast
Incidence of central nervous s ...... zed phase III study CLEOPATRA.
@en
type
label
Incidence of central nervous s ...... zed phase III study CLEOPATRA.
@ast
Incidence of central nervous s ...... zed phase III study CLEOPATRA.
@en
prefLabel
Incidence of central nervous s ...... zed phase III study CLEOPATRA.
@ast
Incidence of central nervous s ...... zed phase III study CLEOPATRA.
@en
P2093
P2860
P356
P1433
P1476
Incidence of central nervous s ...... ized phase III study CLEOPATRA
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDU133
P577
2014-03-31T00:00:00Z